Amgen Announces Top-Line Outcomes of Trial to Reduce Cardiovascular Events With Aranesp Therapy Amgen announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of sufferers with chronic kidney disease , anemia and type-2 diabetes ) Therapy, or TREAT), treatment of anemia with Aranesp ) to a hemoglobin target of 13 g/dL had no statistically significant influence on either of two main endpoints weighed against placebo treatment. The two primary endpoints had been a composite of period to all-cause mortality or cardiovascular morbidity and a composite of time to all-trigger mortality or chronic renal replacement therapy xenical generico .
Amerinet plays a part in Haiti’s relief efforts Amerinet, a leading national healthcare group purchasing firm, has initiated initiatives among employees, suppliers and members to donate to relief efforts for victims of the earthquakes in Haiti. Amerinet in addition has joined the American Hospital Association in encouraging its suppliers and member healthcare services to consider donating via the U.S. Agency for International Development or another well-established, private-sector relief organization. To donate time, cash, equipment or supplies via USAID, please visit For specific inquiries related to complex assistance or commodities donations, visit.